Get the Stockscreener App
3.745
31.89%
0.935
Larimar Therapeutics Inc stock is traded at $3.745, with a volume of 62.27M.
It is up +31.89% in the last 24 hours and up +0.44% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$2.81
Open:
$3.59
24h Volume:
62.27M
Relative Volume:
29.20
Market Cap:
$309.51M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-4.4583
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
+22.31%
1M Performance:
+0.44%
6M Performance:
-5.21%
1Y Performance:
+22.31%
1-Day Range:
$3.55
$4.01
1-Week Range:
$2.715
$4.01
52-Week Range:
$1.61
$5.37
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.725 | 233.48M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.25 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.16 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.81 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.89 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
368.94 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Larimar Soars After FDA Grants Breakthrough Therapy Status To Friedreich's Ataxia Candidate - Nasdaq
Larimar Therapeutics jumps on FDA Breakthrough Therapy Designation for nomlabofusp - Quiver Quantitative
Larimar Therapeutics stock surges on FDA breakthrough status - Investing.com UK
Larimar Therapeutics’ Recent Stock Trends and Financial Insights - timothysykes.com
Larimar Therapeutics (LRMR) Surges on FDA Breakthrough Designati - GuruFocus
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
Larimar Therapeutics' Friedreich's Ataxia Therapy Receives FDA Breakthrough Status; Shares Rise - marketscreener.com
Larimar Therapeutics shares surged 35.6% in pre-market trading after the company announced that its treatment for a neurological disease had received “Breakthrough Therapy” designation from the U.S. Food and Drug Administration (FDA). - Bitget
Larimar stock surges on FDA breakthrough status (LRMR:NASDAQ) - Seeking Alpha
FDA Grants Breakthrough Therapy Status to Larimar’s Nomlabofusp - TipRanks
Larimar Therapeutics announces FDA Breakthrough Therapy Designation for nomlabofusp - marketscreener.com
Larimar Therapeutics wins FDA Breakthrough Therapy Designation for nomlabofusp; BLA on track for June 2026 - TradingView
Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 - Yahoo Finance
IPO Launch: Can Larimar Therapeutics Inc beat the S P 500July 2025 Breakouts & Fast Moving Stock Trade Plans - baoquankhu1.vn
Forecast Cut: Is Larimar Therapeutics Inc being accumulated by smart moneyJuly 2025 Weekly Recap & Short-Term High Return Ideas - baoquankhu1.vn
Is Larimar Therapeutics Inc. impacted by rising ratesCEO Change & Detailed Earnings Play Strategies - mfd.ru
Does Larimar Therapeutics Inc. have consistent dividend growthDollar Strength & Daily Entry Point Trade Alerts - mfd.ru
Investor Mood: Is Larimar Therapeutics Incs growth already priced in2025 Market Trends & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Is Larimar Therapeutics Inc. being accumulated by smart moneyQuarterly Portfolio Summary & Verified Technical Trade Signals - mfd.ru
Does Larimar Therapeutics Inc. have a sustainable dividendWeekly Investment Report & Smart Investment Allocation Insights - mfd.ru
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Gap Down: Will Larimar Therapeutics Inc benefit from geopolitical trendsJuly 2025 Drop Watch & Consistent Return Strategy Ideas - baoquankhu1.vn
Guidance Update: Does Larimar Therapeutics Inc have consistent dividend growthJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Geopolitics Watch: Is Larimar Therapeutics Inc. being accumulated by smart money2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Portfolio Update: Is Smith Douglas Homes Corp a cyclical or defensive stockQuarterly Risk Review & Verified Short-Term Trading Plans - baoquankhu1.vn
Larimar Therapeutics executes strategic stock exchange agreement - MSN
Larimar’s Pediatric Friedreich’s Ataxia Trial Termination: What Investors Should Know - TipRanks
Friedreich's Ataxia Pipeline 2025: FDA Approvals and Clinical - openPR.com
AIGH Capital Management LLC Takes $3.23 Million Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully - Sahm
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care (NASDAQ:LRMR) - Seeking Alpha
Aug Gainers: What risks investors should watch in Larimar Therapeutics Inc stockQuarterly Profit Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
Published on: 2026-01-14 08:49:57 - Bộ Nội Vụ
Death Cross: How Larimar Therapeutics Inc stock performs during Fed tightening cyclesM&A Rumor & Risk Adjusted Buy and Sell Alerts - Bộ Nội Vụ
Published on: 2026-01-13 20:02:33 - Bộ Nội Vụ
Aug Intraday: Will Larimar Therapeutics Inc. stock outperform value stocks2025 Technical Patterns & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Published on: 2026-01-13 12:38:02 - moha.gov.vn
Volatility Watch: Does Larimar Therapeutics Inc have a sustainable dividendTrade Risk Assessment & AI Forecast Swing Trade Picks - baoquankhu1.vn
Will Larimar Therapeutics Inc. stock outperform value stocksTrade Volume Summary & Pattern Based Trade Signal System - ulpravda.ru
Contact | Statesman-ExaminerLarimar Therapeutics, Inc.Common Stock (Nasdaq:LRMR) Detailed Stock Data - FinancialContent
Why Larimar Therapeutics Inc. stock remains resilientRate Cut & AI Powered Market Entry Strategies - Улправда
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN
How Larimar Therapeutics Inc. (ZA71) stock trades after rate cutsMarket Volume Report & Low Risk Entry Point Tips - ulpravda.ru
Will Larimar Therapeutics Inc. (ZA71) stock see valuation expansionWeekly Gains Summary & Weekly Watchlist for Hot Stocks - Улправда
Why Larimar Therapeutics Inc. (ZA71) stock could outperform next yearPortfolio Value Report & Risk Adjusted Buy and Sell Alerts - Улправда
How Larimar Therapeutics Inc. (ZA71) stock correlates with oil marketsRisk Mitigation Techniques & Affordable Market Strategies - ulpravda.ru
Larimar Therapeutics (NASDAQ:LRMR) Raised to "Strong-Buy" at Leerink Partnrs - MarketBeat
How buybacks impact Larimar Therapeutics Inc. stock value2026 world cup usa national team third place match young talents high defensive line group prediction breakdown - Улправда
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):